Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anaerobically cultivated human intestinal microbiota
- Development stage
- Phase 3
- Lead developer
- ACHIM Biotherapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Intracolonic, Oral
01
Overview
Anaerobically cultivated human intestinal microbiota (ACHIM) is an investigational live biotherapeutic product. It is a standardized, complex culture of intestinal flora derived from a healthy donor and propagated in a laboratory under anaerobic conditions. This approach is an alternative to traditional fecal microbiota transplantation (FMT) that uses unprocessed donor stool. The mechanism of action involves restoring a healthy and diverse gut microbiome (eubiosis). This can help outcompete pathogenic bacteria, such as *Clostridium difficile*, and modulate the host's immune system, which is the rationale for its investigation in autoimmune diseases like systemic sclerosis. Clinical trials sponsored by Oslo University Hospital have evaluated ACHIM for the treatment of primary *Clostridium difficile* infection and gastrointestinal symptoms associated with systemic sclerosis.
- Other names
- gut microbiome transplantationGMTfecal microbiota transplantationFMT
Beyond the preview
Go deeper on anaerobically cultivated human intestinal microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anaerobically cultivated human intestinal microbiota.